KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Change in Acquisitions & Divestments (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Change in Acquisitions & Divestments for 9 consecutive years, with $76.0 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Change in Acquisitions & Divestments fell 35.04% year-over-year to $76.0 million, compared with a TTM value of $279.5 million through Mar 2025, down 39.29%, and an annual FY2025 reading of $256.6 million, down 19.92% over the prior year.
  • Change in Acquisitions & Divestments was $76.0 million for Q1 2025 at Biocryst Pharmaceuticals, up from $58.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $148.0 million in Q3 2023 and bottomed at $35.5 million in Q3 2024.
  • Average Change in Acquisitions & Divestments over 3 years is $86.8 million, with a median of $76.0 million recorded in 2025.
  • Peak annual rise in Change in Acquisitions & Divestments hit 180.66% in 2024, while the deepest fall reached 76.03% in 2024.
  • Year by year, Change in Acquisitions & Divestments stood at $129.1 million in 2023, then tumbled by 55.06% to $58.0 million in 2024, then soared by 31.03% to $76.0 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for BCRX at $76.0 million in Q1 2025, $58.0 million in Q4 2024, and $35.5 million in Q3 2024.